Compare Edgewise Therapeutics Inc. Common Stock (EWTX) vs Huntington Ingalls Industries Inc (HII) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Edgewise Therapeutics Inc. Common Stock vs Huntington Ingalls Industries Inc — how do they compare? Edgewise Therapeutics Inc. Common Stock trades at $37.11 (market cap $3.94B), while Huntington Ingalls Industries Inc trades at $265.15 (market cap $10.16B). The key difference: Huntington Ingalls Industries Inc is far larger — about 2.6× Edgewise Therapeutics Inc. Common Stock's market cap, and Huntington Ingalls Industries Inc pays a 2.14% dividend while Edgewise Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Edgewise Therapeutics Inc. Common Stock for 0 Days and Huntington Ingalls Industries Inc for 30 Days on average.
| EWTX | HII | |
|---|---|---|
Market Cap | $3.94B | $10.16B |
Volume | 810,104 | 503,029 |
Sector | Health | Industrials |
52-Week High | $48.35 | $453.73 |
52-Week Low | $14.89 | $257.05 |
Typical Hold Time | 0 Days | 30 Days |
Enterprise Value | $3.48B | $13.08B |
Dividend Yield | — | 2.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
HII trades at $257.84, down 2.34% today, amid a bearish technical signal but strong fundamentals. The company demonstrates consistent earnings beats, with Q2 2026 EPS of $5.27 exceeding expectations by 39%. Recent contract wins, including a $5.1 billion aircraft carrier overhaul and 10 unmanned vessel orders, bolster its $57.3 billion backlog. Valuation metrics appear attractive with a P/E of 15.36 and P/S of 0.77.
The investment case balances strong defense sector positioning against near-term technical weakness. Analyst consensus targets $357.00, implying 38% upside, with 41% buy ratings. Key risks include execution on large contracts and defense budget fluctuations. The current price near support at $258 presents a potential entry point for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Edgewise Therapeutics Inc. Common Stock
Edgewise Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops small-molecule therapies based on its research in muscle physiology, with a pipeline focused on cardiovascular and cardiometabolic conditions such as hypertrophic cardiomyopathy and heart failure.
Read more on EWTX →About Huntington Ingalls Industries Inc
Huntington Ingalls is the largest military shipbuilder in the U.S. and a provider of professional services to government and industry partners, specializing in nuclear-powered submarines and aircraft carriers.
Read more on HII →
